Skip to main content Skip to navigation
Human C4a ELISA Kit

BD OptEIA™ Human C4a ELISA Kit

Product Details
Down Arrow Up Arrow

Human (QC Testing)
ELISA (Routinely Tested)


Activation of the classical or lectin, but not the alternate, complement pathways results in the production of the C4a anaphylatoxin. C4a has been shown to be a weak multi-functional proinflammatory mediator by increasing vascular permeability, and to be spasmogenic.

In blood, plasma or serum, once formed, the nascent C4a anaphylatoxin is rapidly cleaved to the C4a-desArg form by the endogenous serum carboxypeptidase N enzyme. Thus, the quantitation of C4a-desArg in plasma or experimental samples should yield a reliable measurement of the level of classical complement pathway activation that has occurred in the test samples under investigation.

C4a production in vivo may also signal activation of the classical or the lectin complement pathways in several autoimmune diseases including rheumatoid arthritis, lupus erythematosus, and acute glomerulonephritis as well as in early stages of organ transplant rejections.

The BD OptEIATM Human C4a ELISA Kit is for the in vitro quantitative determination of human C4a and the human C4a-desArg in human EDTA plasma, serum and other biological samples.

 Antibody Coated Wells 1 plate (12 strips x 8 wells)
 Detection Antibody 15 mL
 Standards 3 vials, lyophilized
 Enzyme Concentrate (250x) 150


Preparation And Storage

Store unopened reagents at 2-8°C. do not use reagents after expiration date, or if turbidity is evident. Before use, bring all reagents to room temperature (18-25°C). Immediately after use, return to proper storage conditions. Lyophilized standards are stable until expiration date. After reconstitution, immediately aliquot standard stock in polypropylene vials at 50 µl per vial anf freeze at -80°C for up to 6 months. If necessary, store at 2-8°C for up to 8 hours prior to aliquotting/freezing. Do not leave reconstituted standard at room temperature.
550947 Rev. 1
Citations & References
Down Arrow Up Arrow

Development References (7)

  1. Bokisch, VA, and HJ Muller-Eberhard. Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase. J Clin Invest. 1970; 49:2427-36. (Biology).
  2. Ember JA., Jagels MA., Hugli TE. Characterization of complement anaphylatoxins and their biological responses. In: J.E. Volanakis and M.M. Frank, ed. The human complement system in health and disease. Marcel Dekker, Inc; 1998:241-284.
  3. Hugli, TE. Biochemistry and biology of anaphylatoxins. Complement . 1986; 3:108-110. (Biology).
  4. Matsushita, M and T Fujita. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med. 1992; 176:1497-1502. (Biology).
  5. Pfeifer PH, JJ Brehms, M Brunson, and TE Hugli 2000. Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study. Immunopharmacology. 2000; 46:163-174. (Biology).
  6. Pfeifer PH, Kawahara MS, Hugli TE. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem. 1999; 45(8):1190-1199. (Biology). View Reference
  7. Porcel JM, J Ordi, A Castro-Salomo, et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol lmmunopathol. 1995; 74(3):283-8. (Biology).
View All (7) View Less
550947 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.